Payers won’t let these products break the bank.
Conditions require a disciplined approach to drug pricing.
Shift focus in orphan and ultra-orphan messaging to clinical benefit.
Supporting health plan clinical preparation and financial modeling.
Different paths to formulary decision-making.
Reversing non-formulary status will usually require new data.